IBRX is trading 4.7% up at $9.18 as investors continue to re-rate the stock on strong sentiment around its ANKTIVA bladder cancer therapy and positive 2026 regulatory milestones.
- The stock is significantly outperforming broader market indices, supported by a Strong Buy analyst consensus and bullish forecasts highlighting its oncology pipeline.
- Investor confidence remains high following recent clinical data and expectations for upcoming regulatory catalysts through 2026.